While CAR T cell therapy -- a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn -- has revolutionized treatment for many blood cancers ...

Called InflaMix (INFLAmation MIXture Model), the quantitative tool integrates 14 pre-CAR T infusion markers of inflammation and end-organ function into an inflammatory signature that strongly ...

This next-generation CAR T-cell therapy has already been tested in preclinical models of HER2-positive breast cancer derived from patients who have shown a complete, durable, and safe antitumor ...

Source Reference: Good SD, et al "A new toxicity syndrome in patients with autoimmune disease treated with CAR T-cell therapy" Lancet Rheumatol 2025; DOI: 10.1016/S2665-9913 (25)00100-6.

In this study, we assessed the safety, feasibility, and preliminary efficacy of huCART19-IL18 in patients with relapsed or refractory lymphoma after previous anti-CD19 CAR T-cell therapy. Using a ...

Breyanzi is a CAR T therapy for various forms of non-Hodgkin lymphoma. “Breyanzi has demonstrated efficacy and manageable safety in five cancer types, the most of any CD19-directed CAR T-cell ...

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...

A new in vivo approach to chimeric antigen receptor T-cell (CAR-T) therapy could extend the technology’s use beyond cancer, as a treatment for autoimmune disease (Science 2025, DOI: 10.1126 ...

In recent years, CAR-T cell therapy has revolutionized the treatment of patients with so-called "relapsed or refractory (r/r)" aggressive B-cell lymphomas—i.e. lymphoma defined by disease ...

The therapy products affected by the new labeling requirements include: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. The drugmakers have 30 days to comply with the new regulations.

PHILADELPHIA – A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer ...

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...